{"nctId":"NCT03581786","briefTitle":"The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer","startDateStruct":{"date":"2018-10-18","type":"ACTUAL"},"conditions":["Recurrent or Metastatic NPC"],"count":289,"armGroups":[{"label":"placebo combine with chemotherapy","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebos"]},{"label":"TORIPALIMAB INJECTION(JS001 )combine with chemotherapy","type":"EXPERIMENTAL","interventionNames":["Biological: TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy"]}],"interventions":[{"name":"TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy","otherNames":[]},{"name":"Placebos","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 1\\. Age ≥ 18 years and ≤75 years.\n* 2\\. Histological/cytological confirmation of NPC.\n* 3\\. Primarily metastatic (stage IVB as defined by the International Union against Cancer and American Joint Committee on Cancer staging system for NPC, eighth edition) or recurrent NPC that is not amenable for local regional treatment or curative treatment.\n* 4\\. At least 1 measurable lesion according to RECIST version 1.1.\n* 5\\. Life expectancy ≥ 3 months\n\nExclusion Criteria:\n\n* 1\\. History of severe hypersensitivity reactions to other mAbs or any ingredient of JS001.\n* 2\\. Prior therapy targeting PD-1 receptor, or its ligand PD-L1, or cytotoxic T lymphocyte associated protein 4 (CTLA4) receptor.\n* 3\\. Major surgical procedure other than for diagnosis of NPC within 28 days prior to randomization or anticipation of need for a major surgical procedure during the study\n* 4\\. History of hypersensitivity to gemcitabine or cisplatin or to any of the excipients.\n* 5\\. Female patients who are at pregnancy or lactation.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"IRC-assessed Progression-Free Survival (PFS) According to RECIST v1.1","description":"To evaluate the efficacy of JS001 plus chemotherapy compared with placebo plus chemotherapy as measured by IRC-assessed progression free survival (PFS) according to RECIST v1.1 in all patients.\n\nThe definition of Progressive Disease: At least a 20% increasein the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. or the appearance of one or more new lesions is also considered progression.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":null},{"groupId":"OG001","value":"21.4","spread":null}]}]}]},{"type":"SECONDARY","title":"OS","description":"Overall survival was defined as the time from randomization to death from any cause.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.7","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Investigator-assessed ORR According to RECIST v1.1","description":"To evaluate the efficacy of TORIPALIMAB INJECTION(JS001) plus chemotherapy compared with placebo plus chemotherapy, as measured by investigator-assessed overall response rate (ORR) according to RECIST v1.1.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.5","spread":null},{"groupId":"OG001","value":"82.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Investigator-assessed DoR According to RECIST v1.1","description":"To evaluate the efficacy of TORIPALIMAB INJECTION(JS001 )plus chemotherapy compared with placebo plus chemotherapy, as measured by investigator-assessed duration of response (DoR) according to RECIST v1.1.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":null},{"groupId":"OG001","value":"16.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Investigator-assessed DCR According to RECIST v1.1","description":"To evaluate the efficacy of TORIPALIMAB INJECTION(JS001) plus chemotherapy compared with placebo plus chemotherapy, as measured by investigator-assessed disease control rate (DCR) according to RECIST v1.1.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.9","spread":null},{"groupId":"OG001","value":"91.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Investigator-assessed PFS According to RECIST v1.1","description":"To evaluate the efficacy of JS001 plus chemotherapy compared with placebo plus chemotherapy, as measured by Investigators-assessed PFS according to RECIST v1.1","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":null},{"groupId":"OG001","value":"17.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Investigator-assessed PFS Rate at 1 Year","description":"To evaluate the PFS rate at 1 year in each treatment arm by investigator","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.2","spread":null},{"groupId":"OG001","value":"61.4","spread":null}]}]}]},{"type":"SECONDARY","title":"OS Rate at 1 Year","description":"To evaluate the OS rate at 1 year in each treatment arm","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.1","spread":null},{"groupId":"OG001","value":"90.9","spread":null}]}]}]},{"type":"SECONDARY","title":"IRC-assessed ORR According to RECIST v1.1","description":"health related quality of life (HRQoL) in patients treated with JS001 plus chemotherapy compared with placebo plus chemotherapy using the EORTC QLQ-H\\&N35","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.1","spread":null},{"groupId":"OG001","value":"78.8","spread":null}]}]}]},{"type":"SECONDARY","title":"IRC-assessed DoR According to RECIST v1.1","description":"To evaluate the efficacy of JS001 plus chemotherapy compared with placebo plus chemotherapy, as measured by IRC-assessed duration of response (DoR) according to RECIST v1.1.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":null},{"groupId":"OG001","value":"18.0","spread":null}]}]}]},{"type":"SECONDARY","title":"IRC-assessed DCR According to RECIST v1.1","description":"To evaluate the efficacy of JS001 plus chemotherapy compared with placebo plus chemotherapy, as measured by IRC-assessed disease control rate (DCR) according to RECIST v1.1.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.4","spread":null},{"groupId":"OG001","value":"88.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing an Adverse Event(AE)","description":"Incidence of adverse events(AE) as assessed by CTCAE version 5.0","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"143","spread":null},{"groupId":"OG001","value":"146","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-drug Antibody(ADA)","description":"To evaluate the incidence of ADAs against JS001","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"PFS IRC-assessed Per irRECIST","description":"To evaluate PFS of JS001 plus chemotherapy compared with placebo plus chemotherapy according to irRECIST.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null},{"groupId":"OG001","value":"21.6","spread":null}]}]}]},{"type":"SECONDARY","title":"ORR IRC-assessed Per irRECIST","description":"To evaluate ORR of JS001 plus chemotherapy compared with placebo plus chemotherapy according to irRECIST.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.8","spread":null},{"groupId":"OG001","value":"78.8","spread":null}]}]}]},{"type":"SECONDARY","title":"DoR IRC-assessed Per irRECIST","description":"To evaluate DoR of JS001 plus chemotherapy compared with placebo plus chemotherapy according to irRECIST.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null},{"groupId":"OG001","value":"20.1","spread":null}]}]}]},{"type":"SECONDARY","title":"DCR IRC-assessed Per irRECIST","description":"To evaluate DCR of JS001 plus chemotherapy compared with placebo plus chemotherapy according to irRECIST.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.8","spread":null},{"groupId":"OG001","value":"88.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Investigator-assessed PFS Rate at 2 Years","description":"To evaluate the PFS rate at 2 years in each treatment arm by investigator","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.4","spread":null},{"groupId":"OG001","value":"37.0","spread":null}]}]}]},{"type":"SECONDARY","title":"OS Rate at 2 Years","description":"To evaluate the OS rate at 2 years in each treatment arm","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.1","spread":null},{"groupId":"OG001","value":"78.0","spread":null}]}]}]},{"type":"SECONDARY","title":"PFS Investigator-assessed Per irRECIST","description":"To evaluate PFS of JS001 plus chemotherapy compared with placebo plus chemotherapy according to irRECIST.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":null},{"groupId":"OG001","value":"17.3","spread":null}]}]}]},{"type":"SECONDARY","title":"ORR Investigator-assessed Per irRECIST","description":"To evaluate ORR of JS001 plus chemotherapy compared with placebo plus chemotherapy according to irRECIST.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.5","spread":null},{"groupId":"OG001","value":"82.2","spread":null}]}]}]},{"type":"SECONDARY","title":"DoR Investigator-assessed Per irRECIST","description":"To evaluate DoR of JS001 plus chemotherapy compared with placebo plus chemotherapy according to irRECIST.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null},{"groupId":"OG001","value":"16.0","spread":null}]}]}]},{"type":"SECONDARY","title":"DCR Investigator-assessed Per irRECIST","description":"To evaluate DCR of JS001 plus chemotherapy compared with placebo plus chemotherapy according to irRECIST.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.9","spread":null},{"groupId":"OG001","value":"91.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":62,"n":143},"commonTop":["Blood and lymphatic system disorders","Gastrointestinal disorders","Metabolism and nutrition disorders","General disorders and administration site conditions","Investigations"]}}}